COVID-19 and emerging viral infections: The case for interferon lambda (DOI: 10.1084/jem.20200653)

Publication Metadata

DOI	10.1084/jem.20200653
PubMedID	32289152
PMCID	PMC7155807
Sections in this Publication
Section	Section 1: Introduction (from DOI: 10.1084/jem.20200653)
Section	Section 2: IFNs as natural broad-spectrum antivirals (from DOI: 10.1084/jem.20200653)
Section	Section 3: IFN-lambda as an antiviral drug (from DOI: 10.1084/jem.20200653)
Section	Section 4: COVID-19 treatment by IFN-lambda: Pros and cons (from DOI: 10.1084/jem.20200653)
Section	References (from DOI: 10.1084/jem.20200653)
Author(s) [max 10]
1st	Prokunina-Olsson L (1st author of DOI: 10.1084/jem.20200653)
2nd	Alphonse N (2nd author of DOI: 10.1084/jem.20200653)
3rd	Dickenson RE (3rd author of DOI: 10.1084/jem.20200653)
4th	Durbin JE (4th author of DOI: 10.1084/jem.20200653)
5th	Lazear HM (8th author of DOI: 10.1084/jem.20200653)
6th	Hartmann R (6th author of DOI: 10.1084/jem.20200653)
7th	Kotenko SV (7th author of DOI: 10.1084/jem.20200653)
9th	O'Brien TR (9th author of DOI: 10.1084/jem.20200653)
10th	Odendall C (10th author of DOI: 10.1084/jem.20200653)
Dataset	Pubtator Central BioC-JSON formatted article files

Research article published in:
J. Exp. Med.; 2020 05 04 ; 217 (5). DOI: http://doi.org/10.1084/jem.20200653

Abstract

With the first reports on coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the scientific community working in the field of type III IFNs (IFN-lambda) realized that this class of IFNs could play an important role in this and other emerging viral infections. In this Viewpoint, we present our opinion on the benefits and potential limitations of using IFN-lambda to prevent, limit, and treat these dangerous viral infections.

License

This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).